A Prospective Observational Post-Marketing Study of Sovaldi Plus Rebetol in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 May 2017.
- 11 Oct 2016 Planned primary completion date changed from 1 Jun 2018 to 1 May 2017.